Mitochondrial dysfunction is not defined as an isolated “ATP problem” in the Hallmarks of Ageing framework, but as a systemic shift in bioenergetics, redox signaling, quality control and immune metabolism. In the Hallmark update (2023), the mitochondrial axis remains central and explicitly interacts with “disabled macroautophagy”, chronic inflammation and other Hallmarks. For medical practice, this entails a double task: to understand the mechanisms scientifically correctly (including their adaptivity and tissue specificity) and to keep the clinical translation evidence-based – especially where mitochondria-targeted interventions are increasingly marketed as “longevity”, but the data situation is still endpoint- and population-dependent.
Autoren
- Tanja Schliebe
Publikation
- Longevity-Special
You May Also Like
- Psychological dependence on AI assistants, smartphones and short videos
Algorithms, avatars and the unburdened mind
- Psychooncology
Communication as the key to therapy adherence
- The Brain and the Motivation to Eat
Why is it so hard to lose weight?
- Omaveloxolone for Friedreich's Ataxia
Efficacy and Safety Studied Over 6 Years
- Psoriasis: therapy with biologics and TYK-2-i
Progress assessments based on current long-term and real-world data
- Hypertension: the most important facts for daily practice
Early dual antihypertensive therapy is usually indicated
- Escitalopram for anxiety disorders
Positive effect, but no immediate improvement in symptoms
- Helicobacter pylori infection